BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jang JW, Choi JY, Bae SH, Kim CW, Yoon SK, Cho SH, Yang JM, Ahn BM, Lee CD, Lee YS, Chung KW, Sun HS. Transarterial chemo-lipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinoma. J Hepatol. 2004;41:427-435. [PMID: 15336446 DOI: 10.1016/j.jhep.2004.05.014] [Cited by in Crossref: 87] [Cited by in F6Publishing: 82] [Article Influence: 5.4] [Reference Citation Analysis]
Number Citing Articles
1 Jang JW, Choi JY, Bae SH, Yoon SK, Woo HY, Chang UI, Kim CW, Nam SW, Cho SH, Yang JM. The impact of hepatitis B viral load on recurrence after complete necrosis in patients with hepatocellular carcinoma who receive transarterial chemolipiodolization: implications for viral suppression to reduce the risk of cancer recurrence. Cancer. 2007;110:1760-1767. [PMID: 17724708 DOI: 10.1002/cncr.22984] [Cited by in Crossref: 27] [Cited by in F6Publishing: 32] [Article Influence: 1.9] [Reference Citation Analysis]
2 Huang L, Li J, Yan J, Sun J, Zhang X, Wu M, Yan Y. Antiviral therapy decreases viral reactivation in patients with hepatitis B virus-related hepatocellular carcinoma undergoing hepatectomy: a randomized controlled trial. J Viral Hepat. 2013;20:336-342. [PMID: 23565616 DOI: 10.1111/jvh.12036] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 3.4] [Reference Citation Analysis]
3 Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, Guan R, Lau GK, Locarnini S; Chronic Hepatitis B Guideline Working Party of the Asian-Pacific Association for the Study of the Liver. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008;2:263-283. [PMID: 19669255 DOI: 10.1007/s12072-008-9080-3] [Cited by in Crossref: 636] [Cited by in F6Publishing: 660] [Article Influence: 48.9] [Reference Citation Analysis]
4 Lin GN, Peng JW, Xiao JJ, Liu DY, Xia ZJ. Hepatitis B virus reactivation in hepatitis B surface antigen seropositive patients with metastatic non-small cell lung cancer receiving cytotoxic chemotherapy: the efficacy of preemptive lamivudine and identification of risk factors. Med Oncol 2014;31:119. [PMID: 25023055 DOI: 10.1007/s12032-014-0119-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
5 Riedell P, Carson KR. A drug safety evaluation of rituximab and risk of hepatitis B. Expert Opin Drug Saf 2014;13:977-87. [PMID: 24821316 DOI: 10.1517/14740338.2014.918948] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
6 Yu SJ, Lee JH, Jang ES, Cho EJ, Kwak MS, Yoon JH, Lee HS, Kim CY, Kim YJ. Hepatocellular carcinoma: high hepatitis B viral load and mortality in patients treated with transarterial chemoembolization. Radiology. 2013;267:638-647. [PMID: 23440326 DOI: 10.1148/radiol.13121498] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
7 Fu Y, Chung FL. Oxidative stress and hepatocarcinogenesis. Hepatoma Res. 2018;4. [PMID: 30761356 DOI: 10.20517/2394-5079.2018.29] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
8 Ikeda M. Reactivation of hepatitis B virus in patients receiving chemotherapy. Jpn J Clin Oncol. 2013;43:8-16. [PMID: 23183929 DOI: 10.1093/jjco/hys191] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
9 Jang JW, Yoo SH, Nam HC, Jang BH, Sung Sung PS, Lee W, Kwon JH, Nam SW, Bae SH, Yoon SK, Choi JY. Association of Prophylactic Anti-Hepatitis B Virus Therapy With Improved Long-term Survival in Patients With Hepatocellular Carcinoma Undergoing Transarterial Therapy. Clin Infect Dis 2020;71:546-55. [PMID: 31504352 DOI: 10.1093/cid/ciz860] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
10 Su YW, Huang YW, Chen SH, Tzen CY. Quantitative analysis of plasma HBV DNA for early evaluation of the response to transcatheter arterial embolization for HBV-related hepatocellular carcinoma. World J Gastroenterol 2005; 11(39): 6193-6196 [PMID: 16273649 DOI: 10.3748/wjg.v11.i39.6193] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
11 阮杰, 李海军, 孙殿兴. 乙型肝炎病毒的复制再活化. 世界华人消化杂志 2014; 22(7): 927-932 [DOI: 10.11569/wcjd.v22.i7.927] [Reference Citation Analysis]
12 Woo HY, Choi JY, Jang JW, You CR, Bae SH, Yoon SK, Yang JM, Choi SW, Han NI, Kim DG. Role of long-term lamivudine treatment of hepatitis B virus recurrence after liver transplantation. J Med Virol 2008;80:1891-9. [DOI: 10.1002/jmv.21324] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
13 Liu C, Chen P, Chen D, Kao J. Hepatitis B virus reactivation in patients receiving cancer chemotherapy: natural history, pathogenesis, and management. Hepatol Int 2013;7:316-26. [DOI: 10.1007/s12072-011-9279-6] [Cited by in Crossref: 32] [Cited by in F6Publishing: 38] [Article Influence: 3.2] [Reference Citation Analysis]
14 Zhu Y, Cui PJ, Yao J, Zhang ZY, Yang J. Efficacy of Transarterial Chemoembolisation with or without Antiviral Therapy for Patients with Hepatocellular Carcinoma after Radical Hepatectomy. Gastroenterol Res Pract 2018;2018:6414759. [PMID: 29805444 DOI: 10.1155/2018/6414759] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
15 von Weizsäcker F, Blum HE. Out of control: hepatitis B reactivation by transarterial treatment of hepatocellular carcinoma. J Hepatol. 2004;41:482-484. [PMID: 15336452 DOI: 10.1016/j.jhep.2004.07.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
16 Lao XM, Luo G, Ye LT, Luo C, Shi M, Wang D, Guo R, Chen M, Li S, Lin X, Yuan Y. Effects of antiviral therapy on hepatitis B virus reactivation and liver function after resection or chemoembolization for hepatocellular carcinoma. Liver Int 2013;33:595-604. [PMID: 23402625 DOI: 10.1111/liv.12112] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 6.3] [Reference Citation Analysis]
17 Huang L, Li J, Lau WY, Yan J, Zhou F, Liu C, Zhang X, Shen J, Wu M, Yan Y. Perioperative reactivation of hepatitis B virus replication in patients undergoing partial hepatectomy for hepatocellular carcinoma. J Gastroenterol Hepatol. 2012;27:158-164. [PMID: 21871026 DOI: 10.1111/j.1440-1746.2011.06888.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 3.2] [Reference Citation Analysis]
18 Wang X, Yang X, Chen F, Wu S, Song Z, Fei J. Hepatitis B Virus Reactivation Potential Risk Factors in Hepatocellular Carcinoma via Transcatheter Arterial Chemoembolization: A Retrospective Research. Can J Gastroenterol Hepatol 2021;2021:8864655. [PMID: 33505945 DOI: 10.1155/2021/8864655] [Reference Citation Analysis]
19 Thia TJK, Lui HF, Ooi LL, Chung YF, Chow PK, Cheow PC, Tan YM, Chow WC. A Study Into the Risk of Exacerbation of Chronic Hepatitis B After Liver Resection for Hepatocellular Carcinoma. J Gastrointest Surg 2007;11:612-8. [DOI: 10.1007/s11605-007-0121-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
20 Roche B, Samuel D. The difficulties of managing severe hepatitis B virus reactivation. Liver Int. 2011;31 Suppl 1:104-110. [PMID: 21205146 DOI: 10.1111/j.1478-3231.2010.02396.x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 39] [Article Influence: 4.6] [Reference Citation Analysis]
21 Torres HA, Davila M. Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer.Nat Rev Clin Oncol. 2012;9:156-166. [PMID: 22271089 DOI: 10.1038/nrclinonc.2012.1] [Cited by in Crossref: 107] [Cited by in F6Publishing: 90] [Article Influence: 11.9] [Reference Citation Analysis]
22 Choi J, Lim YS. Characteristics, Prevention, and Management of Hepatitis B Virus (HBV) Reactivation in HBV-Infected Patients Who Require Immunosuppressive Therapy. J Infect Dis. 2017;216:S778-S784. [PMID: 29156044 DOI: 10.1093/infdis/jix178] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
23 Zhou J, Sun H, Wang Z, Cong W, Wang J, Zeng M, Zhou W, Bie P, Liu L, Wen T, Han G, Wang M, Liu R, Lu L, Ren Z, Chen M, Zeng Z, Liang P, Liang C, Chen M, Yan F, Wang W, Ji Y, Yun J, Cai D, Chen Y, Cheng W, Cheng S, Dai C, Guo W, Hua B, Huang X, Jia W, Li Y, Li Y, Liang J, Liu T, Lv G, Mao Y, Peng T, Ren W, Shi H, Shi G, Tao K, Wang W, Wang X, Wang Z, Xiang B, Xing B, Xu J, Yang J, Yang J, Yang Y, Yang Y, Ye S, Yin Z, Zhang B, Zhang B, Zhang L, Zhang S, Zhang T, Zhao Y, Zheng H, Zhu J, Zhu K, Liu R, Shi Y, Xiao Y, Dai Z, Teng G, Cai J, Wang W, Cai X, Li Q, Shen F, Qin S, Dong J, Fan J. Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition). Liver Cancer 2020;9:682-720. [PMID: 33442540 DOI: 10.1159/000509424] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 17.0] [Reference Citation Analysis]
24 Lin XJ, Lao XM, Shi M, Li SP. Changes of HBV DNA After Chemoembolization for Hepatocellular Carcinoma and the Efficacy of Antiviral Treatment. Dig Dis Sci 2016;61:2465-76. [PMID: 27105647 DOI: 10.1007/s10620-016-4167-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
25 Sohn W, Paik YH, Cho JY, Ahn JM, Choi GS, Kim JM, Kwon CH, Joh JW, Sinn DH, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC. Influence of hepatitis B virus reactivation on the recurrence of HBV-related hepatocellular carcinoma after curative resection in patients with low viral load. J Viral Hepat 2015;22:539-50. [PMID: 25377516 DOI: 10.1111/jvh.12356] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
26 Park JW, Park KW, Cho SH, Park HS, Lee WJ, Lee DH, Kim CM. Risk of hepatitis B exacerbation is low after transcatheter arterial chemoembolization therapy for patients with HBV-related hepatocellular carcinoma: report of a prospective study. Am J Gastroenterol. 2005;100:2194-2200. [PMID: 16181368 DOI: 10.1111/j.1572-0241.2005.00232.x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 43] [Article Influence: 3.3] [Reference Citation Analysis]
27 Seto WK. Hepatitis B virus reactivation during immunosuppressive therapy: Appropriate risk stratification. World J Hepatol 2015; 7(6): 825-830 [PMID: 25937860 DOI: 10.4254/wjh.v7.i6.825] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
28 Huang G, Lau WY, Wang ZG, Pan ZY, Yuan SX, Shen F, Zhou WP, Wu MC. Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma: a randomized controlled trial. Ann Surg. 2015;261:56-66. [PMID: 25072444 DOI: 10.1097/sla.0000000000000858] [Cited by in Crossref: 104] [Cited by in F6Publishing: 63] [Article Influence: 17.3] [Reference Citation Analysis]
29 Jang JW, Kay CS, You CR, Kim CW, Bae SH, Choi JY, Yoon SK, Han CW, Jung HS, Choi IB. Simultaneous Multitarget Irradiation Using Helical Tomotherapy for Advanced Hepatocellular Carcinoma With Multiple Extrahepatic Metastases. International Journal of Radiation Oncology*Biology*Physics 2009;74:412-8. [DOI: 10.1016/j.ijrobp.2008.08.034] [Cited by in Crossref: 40] [Cited by in F6Publishing: 32] [Article Influence: 3.3] [Reference Citation Analysis]
30 Wong GL. How does hepatitis B virus infection react to hepatocellular carcinoma treatment? J Gastroenterol Hepatol. 2012;27:1-2. [PMID: 22188022 DOI: 10.1111/j.1440-1746.2011.06950.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
31 Liaw YF, Kao JH, Piratvisuth T, Chan HL, Chien RN, Liu CJ, Gane E, Locarnini S, Lim SG, Han KH. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012;6:531-561. [PMID: 26201469 DOI: 10.1007/s12072-012-9365-4] [Cited by in Crossref: 695] [Cited by in F6Publishing: 658] [Article Influence: 77.2] [Reference Citation Analysis]
32 Voican C, Mir O, Loulergue P, Dhooge M, Brezault C, Dréanic J, Chaussade S, Pol S, Coriat R. Hepatitis B virus reactivation in patients with solid tumors receiving systemic anticancer treatment. Annals of Oncology 2016;27:2172-83. [DOI: 10.1093/annonc/mdw414] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 8.4] [Reference Citation Analysis]
33 Jang JW, Choi JY, Bae SH, Yoon SK, Chang UI, Kim CW, Cho SH, Han JY, Lee YS. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology. 2006;43:233-240. [PMID: 16440357 DOI: 10.1002/hep.21024] [Cited by in Crossref: 138] [Cited by in F6Publishing: 133] [Article Influence: 9.2] [Reference Citation Analysis]
34 Huang YW, Chung RT. Management of hepatitis B reactivation in patients receiving cancer chemotherapy. Therap Adv Gastroenterol. 2012;5:359-370. [PMID: 22973419 DOI: 10.1177/1756283x1245024510.1177_1756283x12450245] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
35 Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, Guan R, Lau GK, Locarnini S. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008;2:263-283. [PMID: 19669255 DOI: 10.1007/s12072-008-9080-3.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
36 Watanabe M, Shibuya A, Takada J, Tanaka Y, Okuwaki Y, Minamino T, Hidaka H, Nakazawa T, Koizumi W. Entecavir is an optional agent to prevent hepatitis B virus (HBV) reactivation: a review of 16 patients. Eur J Intern Med. 2010;21:333-337. [PMID: 20603047 DOI: 10.1016/j.ejim.2010.04.010] [Cited by in Crossref: 21] [Cited by in F6Publishing: 27] [Article Influence: 1.9] [Reference Citation Analysis]
37 Morillas RM, López Sisamón D. Reactivación de la hepatitis B asociada a agentes inmunodepresores y a quimioterapia. Historia natural, factores de riesgo y recomendaciones para prevenirla. Medicina Clínica 2019;152:107-14. [DOI: 10.1016/j.medcli.2018.08.018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
38 Lee HL, Bae SH, Jang B, Hwang S, Yang H, Nam HC, Sung PS, Lee SW, Jang JW, Choi JY, Han NI, Song BJ, Lee JW, Yoon SK. Reactivation of Hepatitis C Virus and Its Clinical Outcomes in Patients Treated with Systemic Chemotherapy or Immunosuppressive Therapy.Gut Liver. 2017;11:870-877. [PMID: 28750484 DOI: 10.5009/gnl16434] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
39 Riveiro-Barciela M, Buti M. [Hepatitis B virus infection in pregnancy and the immunosuppressed patient]. Gastroenterol Hepatol 2015;38:31-9. [PMID: 25066320 DOI: 10.1016/j.gastrohep.2014.05.011] [Reference Citation Analysis]
40 Lin CI, Lin ZY, Hsieh MY, Huang CF, Chen SH, Chuang WL. Potential risk factors for the reactivation of the replication of hepatitis B and C viruses after transcatheter arterial chemoembolization of hepatocellular carcinoma. Kaohsiung J Med Sci. 2011;27:554-559. [PMID: 22208538 DOI: 10.1016/j.kjms.2011.06.029] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
41 Huang G, Lai EC, Lau WY, Zhou WP, Shen F, Pan ZY, Fu SY, Wu MC. Posthepatectomy HBV reactivation in hepatitis B-related hepatocellular carcinoma influences postoperative survival in patients with preoperative low HBV-DNA levels. Ann Surg. 2013;257:490-505. [PMID: 22868358 DOI: 10.1097/sla.0b013e318262b218] [Cited by in Crossref: 70] [Cited by in F6Publishing: 37] [Article Influence: 8.8] [Reference Citation Analysis]
42 Li M, Lu C, Cheng J, Zhang J, Cao C, Xu J, Xu J, Pan H, Zhong B, Tucker S. Combination therapy with transarterial chemoembolization and interferon-alpha compared with transarterial chemoembolization alone for hepatitis B virus related unresectable hepatocellular carcinoma. J Gastroenterol Hepatol. 2009;24:1437-1444. [PMID: 19486255 DOI: 10.1111/j.1440-1746.2009.05863.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
43 Zafar H, Ali S. Boron inhibits the proliferating cell nuclear antigen index, molybdenum containing proteins and ameliorates oxidative stress in hepatocellular carcinoma. Archives of Biochemistry and Biophysics 2013;529:66-74. [DOI: 10.1016/j.abb.2012.11.008] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
44 Wang G, Duan Z. Guidelines for Prevention and Treatment of Chronic Hepatitis B. J Clin Transl Hepatol 2021;9:769-91. [PMID: 34722192 DOI: 10.14218/JCTH.2021.00209] [Reference Citation Analysis]
45 Kim MP, Yang JK, Jun BG, Kim YD, Cheon GJ, Jung HJ, Yoo JJ, Kim SG, Kim YS, Jeong SW, Jang JY, Kim HS, Lee SH. Effect of antiviral therapy in patients with low HBV DNA level on transarterial chemoembolization for hepatocellular carcinoma. J Viral Hepat 2021;28:1011-8. [PMID: 33759295 DOI: 10.1111/jvh.13508] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006;43:209-20. [DOI: 10.1002/hep.21051] [Cited by in Crossref: 339] [Cited by in F6Publishing: 308] [Article Influence: 22.6] [Reference Citation Analysis]
47 Korean Liver Cancer Study Group and National Cancer Center, Korea. [Practice guidelines for management of hepatocellular carcinoma 2009]. Korean J Hepatol. 2009;15:391-423. [PMID: 19783891 DOI: 10.3350/kjhep.2009.15.3.391] [Cited by in Crossref: 182] [Cited by in F6Publishing: 180] [Article Influence: 16.5] [Reference Citation Analysis]
48 Jang JW. Management of Patients with Hepatitis B Virus Infection Who Receive Immunosuppressive Treatment or Chemotherapy. Korean J Med 2012;82:149. [DOI: 10.3904/kjm.2012.82.2.149] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
49 You CR, Jang JW, Choi JK, Bae SH, Yoon SK, Kay CS, Choi JY. Hepatic Failure Caused by Reactivation of YMDD Mutants Occurring during Preemptive Lamivudine Therapy. Gut Liver 2010;4:262-5. [PMID: 20559533 DOI: 10.5009/gnl.2010.4.2.262] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
50 Tzeng W, Wu R, Chang S, Chou C, Lin C, Chen J, Yang S, Lin C. Ionic Versus Nonionic Contrast Media Solvents Used with an Epirubicin-based Agent for Transarterial Chemoembolization of Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology 2008;19:342-50. [DOI: 10.1016/j.jvir.2007.10.021] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
51 Mahale P, Kaseb A, Davila M, Torres HA. The effect of transcatheter arterial chemoembolization on hepatitis C viremia. Oncologist 2012;17:e21-3. [PMID: 23002170 DOI: 10.1634/theoncologist.2012-0187] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
52 Yeo W, Chen PJ, Furuse J, Han KH, Hsu C, Lim HY, Moon H, Qin S, Yeoh EM, Ye SL. Eastern Asian expert panel opinion: designing clinical trials of molecular targeted therapy for hepatocellular carcinoma. BMC Cancer 2010;10:620. [PMID: 21062497 DOI: 10.1186/1471-2407-10-620] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
53 Yang ZW, He W, Zheng Y, Zou RH, Liu WW, Zhang YP, Wang CW, Wang YJ, Yuan YC, Li BK, Yuan YF. The efficacy and safety of long- versus short-interval transarterial chemoembolization in unresectable hepatocellular carcinoma. J Cancer 2018;9:4000-8. [PMID: 30410605 DOI: 10.7150/jca.24250] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
54 Ramirez J, Duddempudi AT, Sana MM, Hasan SS, de Los Santos M, Song J, Fang-Hollingsworth Y, Gupta SS, Sears DM. Screening for hepatitis B in patients with lymphoma. Proc (Bayl Univ Med Cent) 2015;28:438-42. [PMID: 26424935 DOI: 10.1080/08998280.2015.11929300] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
55 Xu X, Huang P, Tian H, Chen Y, Ge N, Tang W, Yang B, Xia J. Role of lamivudine with transarterial chemoembolization in the survival of patients with hepatocellular carcinoma. J Gastroenterol Hepatol 2014;29:1273-8. [PMID: 24955456 DOI: 10.1111/jgh.12554] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
56 Gossmann J, Scheuermann EH, Kachel HG, Geiger H, Hauser IA. Reactivation of hepatitis B two years after rituximab therapy in a renal transplant patient with recurrent focal segmental glomerulosclerosis: a note of caution. Clin Transplant. 2009;23:431-434. [PMID: 19077081 DOI: 10.1111/j.1399-0012.2008.00936.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
57 Huang G, Li P, Lau WY, Pan Z, Zhao L, Wang Z, Wang M, Zhou W. Antiviral Therapy Reduces Hepatocellular Carcinoma Recurrence in Patients With Low HBV-DNA Levels: A Randomized Controlled Trial. Annals of Surgery 2018;268:943-54. [DOI: 10.1097/sla.0000000000002727] [Cited by in Crossref: 33] [Cited by in F6Publishing: 20] [Article Influence: 11.0] [Reference Citation Analysis]
58 Liu C, Sun L, Xu J, Zhao Y. Clinical efficacy of postoperative adjuvant transcatheter arterial chemoembolization on hepatocellular carcinoma. World J Surg Oncol. 2016;14:100. [PMID: 27038790 DOI: 10.1186/s12957-016-0855-z] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
59 Yeo W, Chan PK, Hui P, Ho WM, Lam KC, Kwan WH, Zhong S, Johnson PJ. Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. J Med Virol. 2003;70:553-561. [PMID: 12794717 DOI: 10.1002/jmv.10430] [Cited by in Crossref: 149] [Cited by in F6Publishing: 138] [Article Influence: 8.3] [Reference Citation Analysis]
60 Li J, Huang B, Li Y, Zheng D, Zhou Z, Liu J. Hepatitis B virus reactivation in patients with multiple myeloma receiving bortezomib-containing regimens followed by autologous stem cell transplant. Leuk Lymphoma. 2015;56:1710-1717. [PMID: 25098429 DOI: 10.3109/10428194.2014.941833] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 4.5] [Reference Citation Analysis]
61 Huang YW, Chung RT. Management of hepatitis B reactivation in patients receiving cancer chemotherapy. Therap Adv Gastroenterol. 2012;5:359-370. [PMID: 22973419 DOI: 10.1177/1756283X12450245] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
62 Park JW, Amarapurkar D, Chao Y, Chen PJ, Geschwind JF, Goh KL, Han KH, Kudo M, Lee HC, Lee RC, Lesmana LA, Lim HY, Paik SW, Poon RT, Tan CK, Tanwandee T, Teng G, Cheng AL. Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC). Liver Int. 2013;33:327-337. [PMID: 23331661 DOI: 10.1111/liv.12083] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 4.8] [Reference Citation Analysis]
63 Yeo W, Mo FK, Chan SL, Leung NW, Hui P, Lam WY, Mok TS, Lam KC, Ho WM, Koh J, Tang JW, Chan AT, Chan PK. Hepatitis B viral load predicts survival of HCC patients undergoing systemic chemotherapy. Hepatology 2007;45:1382-9. [PMID: 17539025 DOI: 10.1002/hep.21572] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 3.4] [Reference Citation Analysis]
64 Hsieh M, Lin Z, Chen S, Chuang W. Risk factors for the leakage of chemotherapeutic agents into systemic circulation after transcatheter arterial chemoembolization of hepatocellular carcinoma. The Kaohsiung Journal of Medical Sciences 2011;27:431-6. [DOI: 10.1016/j.kjms.2011.06.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
65 Lau GK. Hepatitis B reactivation after chemotherapy: two decades of clinical research. Hepatol Int. 2008;2:152-162. [PMID: 19669300 DOI: 10.1007/s12072-008-9056-3] [Cited by in Crossref: 72] [Cited by in F6Publishing: 70] [Article Influence: 5.5] [Reference Citation Analysis]
66 Shao W, Zhang F, Cong N, Li J, Song J. The hepatitis B virus reactivation after transarterial chemoembolization in Chinese hepatocellular carcinoma patients with low serum hepatitis B virus DNA level. Ther Clin Risk Manag 2015;11:1367-70. [PMID: 26379440 DOI: 10.2147/TCRM.S91618] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
67 Sung PS, Bae SH, Jang JW, Song DS, Kim HY, Yoo SH, Park CH, Kwon JH, Song MJ, You CR, Choi JY, Yoon SK. Differences in the patterns and outcomes of enhanced viral replication between hepatitis C virus and hepatitis B virus in patients with hepatocellular carcinoma during transarterial chemolipiodolization. Korean J Hepatol 2011;17:299-306. [PMID: 22310794 DOI: 10.3350/kjhep.2011.17.4.299] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
68 Zhu SL, Zhong JH, Ke Y, Xiao HM, Ma L, Chen J, You XM, Li LQ. Comparative efficacy of postoperative transarterial chemoembolization with or without antiviral therapy for hepatitis B virus-related hepatocellular carcinoma. Tumour Biol 2015;36:6277-84. [PMID: 25794642 DOI: 10.1007/s13277-015-3313-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
69 Kim TW, Kim MN, Kwon JW, Kim KM, Kim SH, Kim W, Park HW, Chang YS, Cho SH, Min KU. Risk of hepatitis B virus reactivation in patients with asthma or chronic obstructive pulmonary disease treated with corticosteroids. Respirology. 2010;15:1092-1097. [PMID: 20630033 DOI: 10.1111/j.1440-1843.2010.01798.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 30] [Article Influence: 3.5] [Reference Citation Analysis]
70 Lee JI, Kim JK, Chang HY, Lee JW, Kim JM, Chung HJ, Kim YS, Lee KS. Impact of postoperative hepatitis B virus reactivation in hepatocellular carcinoma patients who formerly had naturally suppressed virus. J Gastroenterol Hepatol 2014;29:1019-27. [PMID: 24325315 DOI: 10.1111/jgh.12472] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
71 Xie ZB, Zhu SL, Peng YC, Chen J, Wang XB, Ma L, Bai T, Xiang BD, Li LQ, Zhong JH. Postoperative hepatitis B virus reactivation and surgery-induced immunosuppression in patients with hepatitis B-related hepatocellular carcinoma. J Surg Oncol 2015;112:634-42. [PMID: 26421419 DOI: 10.1002/jso.24044] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
72 Lubel JS, Angus PW. Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: diagnosis and management. J Gastroenterol Hepatol. 2010;25:864-871. [PMID: 20546439 DOI: 10.1111/j.1440-1746.2010.06243.x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 5.1] [Reference Citation Analysis]
73 Lao X, Wang D, Shi M, Liu G, Li S, Guo R, Yuan Y, Chen M, Li J, Zhang Y, Lin X. Changes in hepatitis B virus DNA levels and liver function after transcatheter arterial chemoembolization of hepatocellular carcinoma: HBV DNA and liver function after TACE. Hepatology Research 2011;41:553-63. [DOI: 10.1111/j.1872-034x.2011.00796.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
74 Lau G, Yu ML, Wong G, Thompson A, Ghazinian H, Hou JL, Piratvisuth T, Jia JD, Mizokami M, Cheng G, Chen GF, Liu ZW, Baatarkhuu O, Cheng AL, Ng WL, Lau P, Mok T, Chang JM, Hamid S, Dokmeci AK, Gani RA, Payawal DA, Chow P, Park JW, Strasser SI, Mohamed R, Win KM, Tawesak T, Sarin SK, Omata M. APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy. Hepatol Int 2021;15:1031-48. [PMID: 34427860 DOI: 10.1007/s12072-021-10239-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
75 Shih CA, Chen WC. Prevention of hepatitis B reactivation in patients requiring chemotherapy and immunosuppressive therapy. World J Clin Cases 2021; 9(21): 5769-5781 [PMID: 34368296 DOI: 10.12998/wjcc.v9.i21.5769] [Reference Citation Analysis]
76 Hung H, Su C, Wu J, Lee S. Reactivation of hepatitis B virus after transarterial chemo-embolization for hepatocellular carcinoma in one patient with negative hepatitis B surface antigen. Journal of Hepatology 2010;52:463-5. [DOI: 10.1016/j.jhep.2009.11.023] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
77 Peng JW, Lin GN, Xiao JJ, Jiang XM. Hepatitis B virus reactivation in hepatocellular carcinoma patients undergoing transcatheter arterial chemoembolization therapy. Asia Pac J Clin Oncol. 2012;8:356-361. [PMID: 22897940 DOI: 10.1111/j.1743-7563.2012.01534.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
78 Zhuang L, Zeng X, Yang Z, Meng Z. Effect and safety of interferon for hepatocellular carcinoma: a systematic review and meta-analysis. PLoS One. 2013;8:e61361. [PMID: 24069133 DOI: 10.1371/journal.pone.0061361] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 4.5] [Reference Citation Analysis]
79 Sun Z, Li G, Ai X, Luo B, Wen Y, Zhao Z, Dong S, Guan J. Hepatic and biliary damage after transarterial chemoembolization for malignant hepatic tumors: incidence, diagnosis, treatment, outcome and mechanism. Crit Rev Oncol Hematol 2011;79:164-74. [PMID: 20719529 DOI: 10.1016/j.critrevonc.2010.07.019] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 3.5] [Reference Citation Analysis]
80 Zhang S, Liu J, Zhu J, Xiao M, Lu C, Ni R, Qu L. Effects of TACE and preventive antiviral therapy on HBV reactivation and subsequent hepatitis in hepatocellular carcinoma: a meta-analysis. Japanese Journal of Clinical Oncology 2019;49:646-55. [DOI: 10.1093/jjco/hyz046] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
81 Yu SJ, Kim YJ. Hepatitis B viral load affects prognosis of hepatocellular carcinoma. World J Gastroenterol 2014; 20(34): 12039-12044 [PMID: 25232241 DOI: 10.3748/wjg.v20.i34.12039] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]
82 Jang JW. Hepatitis B virus reactivation in patients with hepatocellular carcinoma undergoing anti-cancer therapy. World J Gastroenterol 2014; 20(24): 7675-7685 [PMID: 24976705 DOI: 10.3748/wjg.v20.i24.7675] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 28] [Article Influence: 3.9] [Reference Citation Analysis]